Neurofeedback with implanted brain electrodes for neurological disorders
Neurofeedback Using Implanted Deep Brain Stimulation Electrodes
NA · ETH Zurich · NCT05101161
This study is testing whether using real-time brain feedback from implanted electrodes can help improve symptoms in people with Parkinson's disease, epilepsy, and essential tremor.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | ETH Zurich (other) |
| Locations | 1 site (Zurich, Canton of Zurich) |
| Trial ID | NCT05101161 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of neurofeedback through implanted deep brain stimulation (DBS) electrodes to treat conditions such as Parkinson's disease, epilepsy, and essential tremor. By analyzing local field potentials (LFP) from the subthalamic nucleus, researchers aim to understand and potentially modulate abnormal neuronal activity associated with these disorders. Patients undergoing the implantation of a Percept™ PC neurostimulator will be monitored for their responses to neurofeedback, providing insights into the correlation between brain activity and motor symptoms. The study seeks to enhance the therapeutic effects of DBS by leveraging real-time feedback from the brain's electrical activity.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are undergoing clinically indicated implantation of a Percept™ PC neurostimulator.
Not a fit: Patients with a minimal prognosticated survival of less than one year or significant concomitant diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved management of symptoms in patients with Parkinson's disease and other neurological disorders.
How similar studies have performed: While deep brain stimulation is a well-established treatment, the specific use of neurofeedback with implanted electrodes is a novel approach that has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: patients undergoing clinically indicated implantation of a Percept™ PC neurostimulator, age ≥ 18 years as well as planned hospitalisation of ≥ 3 days after operation Exclusion Criteria: minimal prognosticated survival of less than 1 year, reduced state of consciousness (i. e. Glasgow Coma Scale \< 15), inability to communicate (in terms of hearing, seeing, speaking and understanding), other significant concomitant diseases (e. g. cardiovascular disease, infectious disease, isolation), inability to follow procedures, insufficient knowledge of project language, inability to give consent and unlikeliness to follow protocol.
Where this trial is running
Zurich, Canton of Zurich
- ETH Zurich — Zurich, Canton of Zurich, Switzerland (RECRUITING)
Study contacts
- Principal investigator: Oliver Bichsel, MD, MSc ETH — ETH Zurich
- Study coordinator: Oliver Bichsel, MD, MSc ETH
- Email: oliver.bichsel@hest.ethz.ch
- Phone: +41 44 510 72 34
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Parkinson Disease, Epilepsy, Essential Tremor